2. Academic Validation
  3. Repurposing Etalocib suppresses multidrug-resistant Staphylococcus aureus by disrupting the bacterial membrane

Repurposing Etalocib suppresses multidrug-resistant Staphylococcus aureus by disrupting the bacterial membrane

  • BMC Microbiol. 2025 Aug 1;25(1):472. doi: 10.1186/s12866-025-04163-5.
Xuancheng Huang # 1 2,  Congcong Li # 2 3,  Chaoqin Zhang # 2,  Yong Xiang 4,  Zhijian Yu 1 2 3,  Peiyu Li 1 2 3,  Bing Bai 5,  Zewen Wen 6 7 8,  Tieying Hou 9 10 11
Affiliations

Affiliations

  • 1 School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, 518055, China.
  • 2 Department of Infectious Diseases and Shenzhen Key Laboratory for Endogenous Infections, Shenzhen Nanshan People's Hospital, Affiliated Nanshan Hospital of Shenzhen University, Nanshan District, No. 89 Taoyuan Road, Shenzhen, 518052, China.
  • 3 School of Basic Medical Sciences, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, 518055, China.
  • 4 Marketing Department of Guangzhou Branch of Varian Medical Equipment Trading (Beijing) Corp, Tianhe District, Rm.2003-20, Leatop Plaza, No. 32 Zhujiang Dong Road, Guangzhou, 510623, P. R. China.
  • 5 Department of Infectious Diseases and Shenzhen Key Laboratory for Endogenous Infections, Shenzhen Nanshan People's Hospital, Affiliated Nanshan Hospital of Shenzhen University, Nanshan District, No. 89 Taoyuan Road, Shenzhen, 518052, China. 568646535@qq.com.
  • 6 School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, 518055, China. wenzw05@163.com.
  • 7 Department of Infectious Diseases and Shenzhen Key Laboratory for Endogenous Infections, Shenzhen Nanshan People's Hospital, Affiliated Nanshan Hospital of Shenzhen University, Nanshan District, No. 89 Taoyuan Road, Shenzhen, 518052, China. wenzw05@163.com.
  • 8 School of Basic Medical Sciences, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, 518055, China. wenzw05@163.com.
  • 9 School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, 518055, China. sz_houtieying@yeah.net.
  • 10 Department of Infectious Diseases and Shenzhen Key Laboratory for Endogenous Infections, Shenzhen Nanshan People's Hospital, Affiliated Nanshan Hospital of Shenzhen University, Nanshan District, No. 89 Taoyuan Road, Shenzhen, 518052, China. sz_houtieying@yeah.net.
  • 11 School of Basic Medical Sciences, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, 518055, China. sz_houtieying@yeah.net.
  • # Contributed equally.
PMID: 40750851 DOI: 10.1186/s12866-025-04163-5
Abstract

Background: The emergence of multidrug-resistant (MDR) Staphylococcus aureus (S. aureus) seriously poses a serious threat to human health and presents a significant clinical challenge. Therefore, it is urgent to explore alternative treatments and develop novel antimicrobial agents. To investigate the Antibacterial activity of Etalocib against S. aureus and elucidate its underlying mechanism of action.

Results: Etalocib, a drug previously investigated in clinical trials, exhibited notable Antibacterial activity against S. aureus, with a minimum inhibitory concentration (MIC) of ≤ 25 μM. Time-kill curves demonstrated concentration-dependent bactericidal effects. Etalocib could significantly inhibited biofilm formation and kill bacteria within mature biofilms. Moreover, permeability assays revealed that Etalocib treatment caused Bacterial membrane damage, accompanied by dissipation of membrane potential. Checkerboard analysis showed that Bacterial membrane Phospholipids, including phosphatidylglycerol and cardiolipin, could neutralize the Antibacterial activity of Etalocib in a dose-dependent manner. These findings suggest that the primary mechanism of action involves disruption of the Bacterial membrane, potentially through interactions with membrane Phospholipids, alterations in protein homeostasis, and disturbances in energy and metabolic processes. Notably, Etalocib significantly improved the survival rate of the Galleria mellonella in the methicillin-resistant S. aureus (MRSA) Infection model.

Conclusions: The findings highlight the potential of Etalocib as an effective Antibacterial agent for combating MDR S. aureus infections. It holds significant promise as a novel therapeutic option for the treatment of severe infections caused by Gram-positive pathogens.

Keywords

S. aureus; Antibacterial effect; Bacterial membrane; Etalocib.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z